Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28718508 | 0.77 | RIPK1 (0.53) | RIPK1SCN9A | |
| SCHEMBL22969007 | 0.77 | DDB1 (0.41) | RIPK1SCN9ADDB1CRBNHTR2A | |
| SCHEMBL19961242 | 0.75 | PSEN1 (0.39) | SCN9AHTR2AHTR2CSLC6A4 | |
| SCHEMBL19960758 | 0.74 | NR1I2 (0.42) | RIPK1DDB1CRBNHTR2AHTR2C | |
| SCHEMBL22968986 | 0.70 | RIPK1 (0.44) | RIPK1HTR2AHTR2CSMN1; SMN2 | |
| SCHEMBL19961238 | 0.70 | NR1I2 (0.36) | RIPK1DDB1CRBNHTR2AHTR2C | |
| SCHEMBL22969000 | 0.69 | SCN9A (0.33) | RIPK1SCN9AGPR119 | |
| Hydrochloric Acid SCHEMBL28709027 | 0.69 | RIPK1 (0.43) | RIPK1HTR2AHTR2CSMN1; SMN2 | |
| SCHEMBL4200172 | 0.67 | DRD2 (0.40) | — | |
| SCHEMBL22969011 | 0.67 | KDM4D (0.36) | RIPK1HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885SCN9A 3101/4885GPR119 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.